Literature DB >> 22754002

Virulence Factors and Anti Fungal Sensitivity Pattern of Candida Sp. Isolated from HIV and TB Patients.

Nachimuthu Ramesh1, Maruthupandian Priyadharsini, Chettipalayam Samiappan Sumathi, Velramar Balasubramanian, Janarthanam Hemapriya, Rajesh Kannan.   

Abstract

The study comprised of 60 Candida spp., 50 isolates from HIV and TB positive individuals (immunocompromised) and 10 isolates from non-HIV and -TB patients (immunocompetent). Among the 60 Candidal isolates, 83.3% were identified as C. albicans, 11.6% as C. glabrata and rest 5% as C. krusei. There is no study in production pattern of extracellular enzymes of Candida spp. isolated from HIV and TB patients in comparison with non-HIV and -TB patients in India. The comparison of phospholipase activities showed that there was a significant difference between the groups at (P = 0.001). The non-HIV and -TB groups of C. glabrata and C. krusei did not show detectable phospholipase activity when compared to the HIV and TB groups. The mean difference in the phospholipase activities of these two groups was significant (P = <0.001). Candida spp. of both the groups do not possess the ability to hydrolyze gelatin. All the strains possessed the ability to show alpha haemolysis. Even though it had shown alpha haemolysis, the significant difference in haemolytic activity was observed only in C. albicans (P = <0.001). None of the isolates from the two groups possessed the ability to hydrolyze gelatin. In the resistance profile of Candida spp., C. albicans of HIV and TB groups had shown resistance to fluconazole, Itraconazole, ketaconazole, nystatin but showed 100% sensitivity towards amphotericin-B. The isolates of C. krusei and C. glabrata showed no resistance to any of the drugs tested. In the case of, non-HIV and -TB patients the resistance pattern was low.

Entities:  

Keywords:  Candida; Fluconazole; HIV; Lipase; Protease; TB

Year:  2011        PMID: 22754002      PMCID: PMC3209911          DOI: 10.1007/s12088-011-0177-3

Source DB:  PubMed          Journal:  Indian J Microbiol        ISSN: 0046-8991            Impact factor:   2.461


  17 in total

1.  Antifungal resistance in pathogenic fungi.

Authors:  Sofia Perea; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2002-11-01       Impact factor: 9.079

Review 2.  Epidemiology of Candida species infections in critically ill non-immunosuppressed patients.

Authors:  Philippe Eggimann; Jorge Garbino; Didier Pittet
Journal:  Lancet Infect Dis       Date:  2003-11       Impact factor: 25.071

3.  Phospholipase and proteinase activities in different Candida species isolated from anatomically distinct sites of healthy adults.

Authors:  Sukru Oksuz; Idris Sahin; Mustafa Yildirim; Aynur Gulcan; Tevfik Yavuz; Demet Kaya; Ayse Nedret Koc
Journal:  Jpn J Infect Dis       Date:  2007-09       Impact factor: 1.362

Review 4.  Candida albicans proteinases and host/pathogen interactions.

Authors:  Julian Naglik; Antje Albrecht; Oliver Bader; Bernhard Hube
Journal:  Cell Microbiol       Date:  2004-10       Impact factor: 3.715

5.  Cluster of oral atypical Candida albicans isolates in a group of human immunodeficiency virus-positive drug users.

Authors:  P Boerlin; F Boerlin-Petzold; C Durussel; M Addo; J L Pagani; J P Chave; J Bille
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

6.  Phospholipase and protease activities in clinical Candida isolates with reference to the sources of strains.

Authors:  A Serda Kantarcioglu; A Yücel
Journal:  Mycoses       Date:  2002-06       Impact factor: 4.377

7.  Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure.

Authors:  E P Milan; M N Burattini; E G Kallás; O Fischmann; P R Costa; A L Colombo
Journal:  Diagn Microbiol Infect Dis       Date:  1998-11       Impact factor: 2.803

8.  Production of a hemolytic factor by Candida albicans.

Authors:  J M Manns; D M Mosser; H R Buckley
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

9.  Lipopolysaccharides of Actinobacillus pleuropneumoniae bind pig hemoglobin.

Authors:  M Bélanger; C Bégin; M Jacques
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

10.  Plate method for detection of phospholipase activity in Candida albicans.

Authors:  M F Price; I D Wilkinson; L O Gentry
Journal:  Sabouraudia       Date:  1982-03
View more
  6 in total

1.  Sub-inhibitory concentrations of antifungals suppress hemolysin activity of oral Candida albicans and Candida tropicalis isolates from HIV-infected individuals.

Authors:  Sukumaran Anil; Mohamed Hashem; Sajith Vellappally; Shankargouda Patil; H M H N Bandara; L P Samaranayake
Journal:  Mycopathologia       Date:  2014-08-21       Impact factor: 2.574

2.  Effect of Nitric Oxide on the Antifungal Activity of Oxidative Stress and Azoles Against Candida albicans.

Authors:  De-Dong Li; Chang-Chun Yang; Ping Liu; Yan Wang; Yan Sun
Journal:  Indian J Microbiol       Date:  2016-04-09       Impact factor: 2.461

Review 3.  Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development.

Authors:  Małgorzata Bondaryk; Wiesław Kurzątkowski; Monika Staniszewska
Journal:  Postepy Dermatol Alergol       Date:  2013-10-30       Impact factor: 1.837

4.  Virulence factors, antifungal susceptibility and molecular mechanisms of azole resistance among Candida parapsilosis complex isolates recovered from clinical specimens.

Authors:  Sourour Neji; Ines Hadrich; Houaida Trabelsi; Salma Abbes; Fatma Cheikhrouhou; Hayet Sellami; Fattouma Makni; Ali Ayadi
Journal:  J Biomed Sci       Date:  2017-09-04       Impact factor: 8.410

5.  Evaluation of esterase and hemolysin activities of different Candida species isolated from vulvovaginitis cases in Lorestan Province, Iran.

Authors:  Maryam Noori; Mohammad Dakhili; Asghar Sepahvand; Nader Davari
Journal:  Curr Med Mycol       Date:  2017-12

6.  Silymarin, a Popular Dietary Supplement Shows Anti-Candida Activity.

Authors:  Monika Janeczko; Elżbieta Kochanowicz
Journal:  Antibiotics (Basel)       Date:  2019-10-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.